CellProthera SAS, a biotechnology company currently in the clinical phase with a novel cell therapy for the regeneration of damaged heart tissue and other impaired organs. It has strengthened its leadership team to support its key clinical program and expand it to new therapeutic indications.

Ibon Garitaonandia becomes Chief Scientific Officer (CSO). His extensive experience in drug discovery and the development of novel stem cell products will accelerate the transfer of CellProthera's cell therapy platform to new treatment options in the field of regenerative medicine. With 15 years of experience in stem cell research and regenerative medicine, he has worked at the Richmond Research Institute in London, Histocell in Spain and the International StemCell Corporation in California, the first company to receive worldwide approval for received a clinical study on the treatment of Parkinson's disease using human pluripotent stem cells.

Henk Streefkerk, MD PhD, will take on the role of Chief Medical Officer (CMO). He has decades of clinical research experience that will drive the company's strategic development and expand the pipeline of novel therapy options. After completing his studies at the University Medical Center Utrecht, Henk worked as a clinical pharmacologist for Organon / Schering-Plow in the Netherlands. He later moved to Actelion in Switzerland before working at Novartis in Basel as an expert in translational medicine and later as Senior Brand Safety Leader. After his career at Novartis, he was Medical Director and Chief Medical Officer of a biotech company specializing in oncology in Basel.

Olivier Friedrich is appointed Chief Financial Officer (CFO). His solid experience in promoting the development of companies and startups is central to CellProthera as it moves to the next stage of development. Olivier is a lecturer in finance and regulation at EM Strasbourg and has 15 years of experience in corporate finance, internal control, accounting and taxation. He spent more than 10 years in senior positions at Ernst & Young, where he led financial audits and due diligence transactions for a wide range of industrial companies and, as CFO, supported the cash and finance management of listed companies in the energy and automotive sectors.

"The appointment of these three talents and proven experts in their respective fields to the management team is an enormous benefit for our ambitious development program for multiple indications and puts us in an ideal position to accelerate the path to market readiness", reports Matthieu de Kalbermatten, Chairman at CellProthera. "Your extensive international experience will help us to optimally position the company in the next clinical and regulatory phases and to keep it on course."

CellProthera is developing a medical innovation that enables a heart damaged by a heart attack to be regenerated from the patient's own blood using injected stem cells.

This approach makes the patient the source of his own medicine!

Das Stammzellprodukt ProtheraCytes® wird mit einer von CellProthera entwickelten Technologie produziert und in das zu regenerierende Herzgewebe injiziert. Nach einigen Monaten erlangt der Herzmuskel seine Funktionstüchtigkeit wieder, sodass künftige, oft stark beeinträchtigende Behandlungen oder sogar eine Herztransplantation vermieden werden können.

Nehmen Sie mit uns Kontakt auf! www.cellprothera.com/fr/

Die offizielle, autorisierte Version dieser Pressemitteilung ist die englischsprachige Originalfassung. Übersetzungen werden lediglich zum besseren Verständnis angeboten und sollten stets mit der Originalfassung verglichen werden, die als einzige Version dieses Textes rechtlich verbindlich ist.

Contacts
Ansprechpartner
Pressekontakt: Mediatiser – Antoine Monnier / amonnier@mediatiser.tv

Source:businesswire.com

Report Abuse